Alx Oncology Holdings (ALXO) Net Cash Flow (2019 - 2026)

Alx Oncology Holdings has reported Net Cash Flow for 8 years, with the latest figure at $15.9 million in Q1 2026.

• Quarterly Net Cash Flow rose 422.19% year-over-year to $15.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.7 million (up 77.54% YoY) and the FY2025 annual result came in at -$1.2 million, up 75.33% from the prior year.
• Net Cash Flow climbed to $15.9 million in Q1 2026 per ALXO's latest filing, from -$7.1 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $15.9 million in Q1 2026 and troughed at -$204.5 million in Q1 2022.
• A 5-year average of -$19.5 million and a median of -$232000.0 in 2022 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2022 and 2023: Net Cash Flow sank 4586.41% in 2022, then jumped 1316.38% in 2023.
• Over 5 years, Net Cash Flow stood at -$232000.0 in 2022, then surged by 1316.38% to $2.8 million in 2023, then plunged by 48.09% to $1.5 million in 2024, then slumped by 582.53% to -$7.1 million in 2025, then jumped by 325.08% to $15.9 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $15.9 million, -$7.1 million, and $4.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.